FDA to expedite review of Lilly's gastric cancer drug

10/25/2013 | Pharmaceutical Business Review Online

The FDA granted priority-review designation to Eli Lilly & Co.'s biologics license application for ramucirumab, or IMC-1121B, for treatment of patients with advanced gastric cancer whose disease progressed after initial chemotherapy. The drug is also under regulatory review in Europe.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR